Home » Stocks » CGEM

Cullinan Management, Inc. (CGEM)

Stock Price: $32.48 USD -1.36 (-4.02%)
Updated Apr 22, 2021 4:00 PM EDT - Market closed
Market Cap 1.28B
Revenue (ttm) n/a
Net Income (ttm) -51.80M
Shares Out 39.50M
EPS (ttm) -1.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 22
Last Price $32.48
Previous Close $33.84
Change ($) -1.36
Change (%) -4.02%
Day's Open 33.70
Day's Range 31.94 - 34.83
Day's Volume 117,163
52-Week Range 27.01 - 59.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) announced today that the company's Chief Financial Officer, Jeff Trigilio, will present at the up...

2 weeks ago - GlobeNewsWire

Pipeline Progress: Clinical and preclinical programs continue to advance, with encouraging initial Cullinan Pearl data and additional INDs to be filed in 2021 for immuno-oncology assets Cullinan Florent...

3 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology an...

1 month ago - GlobeNewsWire

February 22, 2021

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-onc...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Please note that the embedded hyperlinks in the press release below have been corrected from a release issued under the same headline earlier today.

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc., a biopharmaceutical company focused on developing a diversified pipeline...

3 months ago - GlobeNewswire

Cullinan Management, a Phase 1/2a biotech developing and investing in oncology therapies, raised the proposed deal size for its upcoming IPO on Wednesday.

3 months ago - NASDAQ

- Zai Lab to lead development and commercialization of CLN-081 in Greater China - Cullinan will receive $20 million upfront, up to $211 million in...

3 months ago - GlobeNewswire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cullinan Oncology, LLC, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative...

4 months ago - Business Wire

Cullinan Management, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

About CGEM

Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. Our strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that we believe have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes. In approximately three and a h... [Read more...]

Industry
Biotechnology
IPO Date
Jan 8, 2021
CEO
Owen Hughes
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
CGEM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for CGEM is 47.75, which is an increase of 47.01% from the latest price.

Price Target
$47.75
(47.01% upside)